Royalty Short Term Investments from 2010 to 2025

RPRX Stock

USD 31.65 0.09 0.29%

Royalty Pharma Short Term Investments yearly trend continues to be fairly stable with very little volatility. Short Term Investments will likely drop to about 55.3 M in 2025. During the period from 2010 to 2025, Royalty Pharma Short Term Investments regression line of annual values had r-squared of 0.0004 and arithmetic mean of 457,660,625. View All Fundamentals

Short Term Investments

First Reported

2007-03-31

Previous Quarter

48.5 M

Current Value

842 M

Quarterly Volatility

542.7 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.

Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Short Term Investments Growth Pattern

Below is the plot of the Short Term Investments of Royalty Pharma Plc over the last few years. Short Term Investments is an item under the current assets section of Royalty Pharma balance sheet. It contains any investments Royalty Pharma Plc undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Royalty Pharma Plc can easily liquidate in the marketplace. It is Royalty Pharma's Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.

Short Term Investments

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Short Term Investments

Timeline

Royalty Short Term Investments Regression Statistics

	Arithmetic Mean	457,660,625
	Geometric Mean	279,009,620
	Coefficient Of Variation	73.46
	Mean Deviation	209,304,438
	Median	461,821,000
	Standard Deviation	336,215,958
	Sample Variance	113041.2T
	Range	1.2B
	R-Value	0.02
	Mean Square Error	121064.5T
	R-Squared	0.0004
	Significance	0.94
	Slope	1,450,153
	Total Sum of Squares	1695617.6T

Royalty Short Term Investments History

	2025	55.3 M
	2024	58.2 M
	2023	18.3 M
	2022	717 M
	2021	1.3 B
	2020	983 M
	2019	509.5 M

Other Fundumenentals of Royalty Pharma Plc

Cash And Short Term Investments

Royalty Pharma Short Term Investments component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Net Debt	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue	Capital Surpluse
Total Assets		0.96	0.84	0.19	0.96	-0.23	0.16	-0.37	-0.23	0.93	0.92	0.86	0.71	0.24	0.05	0.28	0.66	0.86	0.82	-0.85	-0.4	0.42	-0.42	0.67
Total Stockholder Equity	0.96		0.9	0.01	0.91	-0.23	0.12	-0.34	-0.25	0.86	0.88	0.74	0.78	0.25	-0.11	0.33	0.71	0.85	0.77	-0.81	-0.55	0.3	-0.6	0.68
Accounts Payable	0.84	0.9		-0.24	0.78	-0.2	0.03	-0.27	-0.36	0.78	0.86	0.48	0.84	0.12	0.12	0.2	0.75	0.87	0.73	-0.77	-0.73	0.16	-0.56	0.71
Short Term Investments	0.19	0.01	-0.24		0.11	0.32	0.03	-0.34	0.15	0.18	0.11	0.42	-0.21	0.03	-0.16	-0.05	-0.23	0.01	0.17	-0.14	0.6	0.51	0.44	-0.22
Total Liab	0.96	0.91	0.78	0.11		-0.33	0.37	-0.38	-0.12	0.95	0.92	0.89	0.71	0.29	0.05	0.33	0.68	0.77	0.68	-0.72	-0.46	0.4	-0.43	0.64
Treasury Stock	-0.23	-0.23	-0.2	0.32	-0.33		-0.42	-0.68	0.09	-0.31	-0.28	-0.26	-0.18	-0.03	0.06	-0.04	-0.15	-0.08	0.01	0.01	0.22	0.0	0.1	-0.07
Common Stock	0.16	0.12	0.03	0.03	0.37	-0.42		-0.16	0.54	0.37	0.28	0.34	-0.03	-0.24	-0.16	-0.25	-0.14	-0.24	-0.36	0.37	-0.14	-0.2	0.17	-0.31
Property Plant Equipment	-0.37	-0.34	-0.27	-0.34	-0.38	-0.68	-0.16		-0.27	-0.37	-0.36	-0.34	-0.25	-0.07	-0.03	-0.08	-0.23	-0.28	-0.26	0.26	0.16	-0.14	0.12	-0.22
Intangible Assets	-0.23	-0.25	-0.36	0.15	-0.12	0.09	0.54	-0.27		-0.13	-0.2	-0.01	-0.4	-0.32	-0.13	-0.34	-0.45	-0.5	-0.49	0.51	0.21	-0.32	0.31	-0.51
Net Tangible Assets	0.93	0.86	0.78	0.18	0.95	-0.31	0.37	-0.37	-0.13		0.98	0.83	0.73	0.15	0.12	0.23	0.66	0.79	0.72	-0.7	-0.45	0.39	-0.22	0.63
Retained Earnings	0.92	0.88	0.86	0.11	0.92	-0.28	0.28	-0.36	-0.2	0.98		0.74	0.82	0.16	0.08	0.25	0.73	0.85	0.75	-0.73	-0.54	0.39	-0.29	0.67
Total Current Assets	0.86	0.74	0.48	0.42	0.89	-0.26	0.34	-0.34	-0.01	0.83	0.74		0.37	0.22	0.05	0.23	0.37	0.57	0.63	-0.64	-0.02	0.45	-0.15	0.43
Net Debt	0.71	0.78	0.84	-0.21	0.71	-0.18	-0.03	-0.25	-0.4	0.73	0.82	0.37		0.43	-0.05	0.55	0.96	0.88	0.69	-0.7	-0.79	0.38	-0.63	0.85
Long Term Debt	0.24	0.25	0.12	0.03	0.29	-0.03	-0.24	-0.07	-0.32	0.15	0.16	0.22	0.43		-0.3	0.96	0.59	0.38	0.3	-0.37	-0.07	0.78	-0.59	0.54
Net Receivables	0.05	-0.11	0.12	-0.16	0.05	0.06	-0.16	-0.03	-0.13	0.12	0.08	0.05	-0.05	-0.3		-0.34	0.04	0.16	0.24	-0.21	-0.07	-0.12	0.32	0.23
Long Term Debt Total	0.28	0.33	0.2	-0.05	0.33	-0.04	-0.25	-0.08	-0.34	0.23	0.25	0.23	0.55	0.96	-0.34		0.69	0.47	0.39	-0.42	-0.18	0.7	-0.62	0.66
Net Invested Capital	0.66	0.71	0.75	-0.23	0.68	-0.15	-0.14	-0.23	-0.45	0.66	0.73	0.37	0.96	0.59	0.04	0.69		0.87	0.71	-0.72	-0.73	0.47	-0.67	0.94
Long Term Investments	0.86	0.85	0.87	0.01	0.77	-0.08	-0.24	-0.28	-0.5	0.79	0.85	0.57	0.88	0.38	0.16	0.47	0.87		0.94	-0.95	-0.54	0.5	-0.51	0.9
Short Long Term Debt	0.82	0.77	0.73	0.17	0.68	0.01	-0.36	-0.26	-0.49	0.72	0.75	0.63	0.69	0.3	0.24	0.39	0.71	0.94		-0.97	-0.27	0.5	-0.32	0.83
Capital Stock	-0.85	-0.81	-0.77	-0.14	-0.72	0.01	0.37	0.26	0.51	-0.7	-0.73	-0.64	-0.7	-0.37	-0.21	-0.42	-0.72	-0.95	-0.97		0.31	-0.53	0.46	-0.83
Net Working Capital	-0.4	-0.55	-0.73	0.6	-0.46	0.22	-0.14	0.16	0.21	-0.45	-0.54	-0.02	-0.79	-0.07	-0.07	-0.18	-0.73	-0.54	-0.27	0.31		0.18	0.63	-0.58
Short Term Debt	0.42	0.3	0.16	0.51	0.4	0.0	-0.2	-0.14	-0.32	0.39	0.39	0.45	0.38	0.78	-0.12	0.7	0.47	0.5	0.5	-0.53	0.18		-0.14	0.45
Current Deferred Revenue	-0.42	-0.6	-0.56	0.44	-0.43	0.1	0.17	0.12	0.31	-0.22	-0.29	-0.15	-0.63	-0.59	0.32	-0.62	-0.67	-0.51	-0.32	0.46	0.63	-0.14		-0.59
Capital Surpluse	0.67	0.68	0.71	-0.22	0.64	-0.07	-0.31	-0.22	-0.51	0.63	0.67	0.43	0.85	0.54	0.23	0.66	0.94	0.9	0.83	-0.83	-0.58	0.45	-0.59

Click cells to compare fundamentals

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Short Term Investments, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Short Term Investments	58.2 M	55.3 M
Cash And Short Term Investments	987.2 M	1.4 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Short Term Investments from 2010 to 2025

Latest Royalty Pharma's Short Term Investments Growth Pattern

Royalty Short Term Investments Regression Statistics

Royalty Short Term Investments History

Other Fundumenentals of Royalty Pharma Plc

Royalty Pharma Short Term Investments component correlations

About Royalty Pharma Financial Statements

Also Currently Popular

Additional Tools for Royalty Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY